Expression and correlation analysis of forkhead box protein P3 positive regulatory T cells and programmed death-1/programmed death-ligand 1 pathway in early gastric cancer
QIN Yucui1 XIA Yun2▲
1.Health Management Centre, Nanjing Pukou District Hospital of Traditional Chinese Medicine, Jiangsu Province, Nanjing 211800, China;
2.Department of Spleen and Stomach, Nanjing Pukou District Hospital of Traditional Chinese Medicine, Jiangsu Province, Nanjing 211800, China
Abstract：Objective To investigate the expression and correlation of forkhead box protein P3 positive regulatory T cells (FOXP3+Tregs) and programmed death-1 (PD-1) / programmed death-ligand 1 (PD-L1) pathway in patients with early gastric cancer. Methods Gastric mucosa tissues of ten patients with early gastric cancer (early gastric cancer group) and ten patients with chronic gastritis (control group) admitted to Nanjing Pukou District Hospital of Traditional Chinese Medicine from October 2020 to June 2022 were collected. Tissue immunofluorescence was used to detect the expression of FOXP3+Tregs and PD-1/PD-L1 pathway in the gastric mucosa of the early gastric cancer group and the control group, and the correlation between the expression of them in early gastric cancer tissues was analyzed. Results The expression levels of FOXP3+Tregs, PD-1, and PD-L1 in the early gastric cancer group were higher than those in the control group, and the differences were statistically significant (P＜0.05 or P＜0.01). FOXP3+Tregs were positively correlated with PD-1 and PD-L1 expression in gastric mucosa of early gastric cancer group (r＞0, P＜0.01). Conclusion FOXP3+Tregs and PD-1/PD-L1 pathway are co-expressed in early gastric cancer tissues, suggesting that the combination of them can provide important reference for the determination of clinical early gastric cancer.
[1] 孙凯旋，张眉佳，廖成功，等.中国人群胃癌发病影响因素的Meta分析[J].现代肿瘤医学，2022，30（8）：1431-1438.
[2] Eusebi LH，Telese A，Marasco G，et al. Gastric cancer prevention strategies：A global perspective [J]. J Gastroenterol Hepatol，2020，35（9）：1495-1502.
[3] Elsheshtawy NM，Saad M，El-Ghamrini YM，et al. Determination of a CD4+CD25+ Foxp3+T cells subset in Egyptian Colorectal Cancer Patients [J]. Egypt J Immunol，2021，28（3）：145-156.
[4] Yang S，Liu Y，Li MY，et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer [J]. Mol Cancer，2017，16（1）：124.
[5] Li X，Ma K，Song S，et al. Tight correlation between FoxM1 and FoxP3+ Tregs in gastric cancer and their clinical significance [J]. Clin Exp Med，2018，18（3）：413-420.
[6] 鞠晓静.Foxp3+调节性T细胞及程序性死亡受体1在胃癌组织中的表达及其临床病理意义[J].医学信息，2021， 34（2）：105-107，112.
[7] 韩乔，梁冠中，郑健，等.程序性死亡受体1及程序性死亡受体配体1表达在肺癌中的研究进展[J].肿瘤研究与临床，2019，31（5）：354-357.
[8] Laumont CM，Wouters M，Smazynski J，et al. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39，CD103，and PD-1 in Ovarian Cancer [J]. Clin Cancer Res，2021，27（14）：4089-4100.
[9] Hall M，Liu H，Malafa M，et al. Expansion of tumor-infiltrating lymphocytes（TIL）from human pancreatic tumors [J]. J Immunother Cancer，2016，4：61.
[10] Li Y，Liang L，Dai W，et al. Prognostic impact of programed cell death-1（PD-1）and PD-ligand 1（PD-L1）expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer [J]. Mol Cancer，2016，15（1）：55.
[11] 朱军，黄美金，陈宏.进展期胃癌免疫治疗的研究进展[J].癌症进展，2022，20（12）：1189-1193.
[12] Douda L，Cyrany J，Tachecí I. Early gastric cancer [J]. Vnitr Lek，2022，68（6）：371-375.
[13] Stewart OA，Wu F，Chen Y. The role of gastric microbiota in gastric cancer [J]. Gut Microbes，2020，11（5）：1220-1230.
[14] Dai D，Yang Y，Yu J，et al. Interactions between gastric microbiota and metabolites in gastric cancer [J]. Cell Death Dis，2021，12（12）：1104.
[15] 吕彩霞，苑晓烨，邵伟华，等.黄芪多糖对老年晚期胃癌病人外周血中调节性T细胞的影响[J].实用老年医学，2021，35（6）：564-567.
[16] Sakaguchi S，Mikami N，Wing JB，et al. Regulatory T Cells and Human Disease [J]. Annu Rev Immunol，2020，38：541- 566.
[17] Wang HY，Wang RF. Regulatory T cells and cancer [J]. Curr Opin Immunol，2007，19（2）：217-223.
[18] 周岳，李晓辉.胃癌患者肿瘤血液免疫指标与术后并发症的关系分析[J].检验医学与临床，2022，19（17）：2309- 2313.
[19] 张帆，邸泰霖，韩克松.NK、Th17和Treg细胞水平对结直肠癌患者术后复发预测价值的分析[J].中国中西医结合外科杂志，2019，25（4）：448-452.
[20] 侯婧瑛，向仍运，陈淑芬，等.Foxp3+Tregs和PD1在胃癌组织中的表达及其临床病理意义[J].中国病理生理杂志，2015，31（10）：1744-1749.
[21] 张岩雪，李红艳，孙军华，等.基于PD-1/PD-L1信号通路探讨妇炎汤对慢性盆腔炎小鼠Treg/Th17免疫平衡的影响[J].中国优生与遗传杂志，2022，30（5）：744-749.
[22] 田文霞，赵玲，孟宪霞.免疫卡控点PD-1/PD-L1在肿瘤免疫中的研究进展[J].中国医药科学，2022，12（8）：64-67.
[23] 鲍欣，刘爽，张弘.PD-1/PD-L1抑制剂在未分化甲状腺癌中的研究进展[J].疑难病杂志，2022，21（6）：656-659， 664.
[24] 叶为，臧晋.PD-1/PD-L1抑制剂治疗肌层浸润性膀胱癌的研究进展[J].中国医药科学，2023，13（8）：55-58.
[25] Han Y，Liu D，Li L. PD-1/PD-L1 pathway：current researches in cancer [J]. Am J Cancer Res，2020，10（3）：727-742.
[26] Dantoing E，Piton N，Salaün M，et al. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations [J]. Int J Mol Sci，2021， 22（12）：6288.
[27] Braun DA，Hou Y，Bakouny Z，et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma [J]. Nat Med，2020，26（6）：909-918.
[28] 朱云，吴东娟，马帅军，等.外周血PD-1、PD-L1表达与肾细胞癌骨转移的相关性分析[J].疑难病杂志，2022， 21（5）：497-501.
[29] 陈广玉.PD-1抗体增强结肠癌中肿瘤浸润淋巴细胞抗肿瘤作用研究[D].新乡：新乡医学院，2020.
[30] Jin HT，Ahmed R，Okazaki T. Role of PD-1 in regulating T-cell immunity [J]. Curr Top Microbiol Immunol，2011，350： 17-37.
京公网安备 11010502046598号